The prothrombin consumption test (PCT) is a classic coagulation screening assay that measures residual prothrombin activity in serum after whole blood clots in vitro, providing a functional evaluation of the intrinsic coagulation pathway and platelet factor 3 availability. This article reviews the test principle, sample requirements, methodology, interpretation criteria, quality control considerations, and clinical applications for laboratory professionals and clinicians.
Technical Overview
The prothrombin consumption test, also known as the serum prothrombin time test or prothrombin utilization test, is a legacy coagulation assay originally described by Armand Quick and colleagues in the mid-twentieth century. Its purpose is to assess how efficiently prothrombin is converted into thrombin during the process of blood coagulation in a glass tube.
The test is based on the physiology of the coagulation cascade. When native blood clots in vitro, the intrinsic pathway generates a potent thromboplastin complex through the sequential activation of coagulation factors XII, XI, IX, and VIII, supported by platelet factor 3 (platelet-derived phospholipid). This complex, together with factor X and factor V, converts prothrombin into thrombin. In normal hemostasis, the vast majority of available prothrombin is consumed during clot formation, leaving only a small residual amount in the serum.
The assay quantifies the prothrombin remaining in serum after clotting. If the intrinsic pathway or platelet factor 3 function is defective, thromboplastin generation is impaired, prothrombin is poorly consumed, and measurable residual prothrombin in the serum increases. Consequently, the serum prothrombin time is shortened compared with normal. Conversely, in healthy individuals the serum prothrombin time is markedly prolonged because very little prothrombin remains. The test therefore serves as an indirect but integrated functional readout of intrinsic pathway activity and platelet procoagulant activity.
Although the prothrombin consumption test has largely been superseded in modern laboratories by the activated partial thromboplastin time (APTT), specific factor assays, and automated platelet function testing, it remains a valuable screening tool in resource-limited settings, in teaching laboratories, and as a complementary assay in selected diagnostic workflows.
Testing Samples
Native Whole Blood
The primary specimen is fresh venous blood collected by clean venipuncture directly into a plain, clean glass tube without any anticoagulant. A typical volume of 1 to 2 mL is sufficient. The venipuncture must be technically clean, because contamination with tissue thromboplastin from the puncture site can activate the extrinsic pathway and falsely normalize the result.
Serum Derived After Clotting
The collected blood is allowed to clot undisturbed in a water bath or heat block at 37°C. After clot formation, the specimen is incubated for a standardized period, commonly one hour, and then centrifuged to obtain clear serum. The serum must be free of hemolysis, residual cells, and fibrin clots before analysis.
Pre-Analytical Requirements
- Use scrupulously clean, non-siliconized glass tubes to ensure consistent contact activation of the intrinsic pathway.
- Avoid traumatic venipuncture, prolonged tourniquet application, frothing, or mixing with tissue fluid.
- Process the specimen at a controlled temperature of 37°C throughout clotting and incubation.
- Test the harvested serum promptly, as delayed testing may alter residual prothrombin activity.
- Collect and run a normal control blood specimen in parallel with every patient sample.
Testing Items
The prothrombin consumption test evaluates the following measurable outputs:
- Serum prothrombin time, expressed in seconds, which reflects the residual prothrombin activity remaining in serum after in vitro clotting.
- Prothrombin consumption index, a derived ratio comparing the patient plasma and serum prothrombin times, which normalizes the result and expresses the degree of prothrombin utilization.
- Corrective (correction) studies, in which the patient specimen is supplemented with normal adsorbed plasma, normal serum, or platelet phospholipid substitute to localize the defect to factor VIII or XI deficiency, factor IX deficiency, or platelet factor 3 dysfunction respectively.
Reference intervals are laboratory-specific and method-dependent. In many protocols, a serum prothrombin time greater than approximately 25 seconds indicates normal prothrombin consumption, whereas a value persistently below the laboratory-defined threshold indicates defective consumption. Each laboratory must establish and validate its own reference range using local reagents and instrumentation, consistent with quality management frameworks such as ISO 15189.
Testing Methods
Classic Serum Prothrombin Time Procedure
The conventional method follows a standardized sequence:
- Perform a clean venipuncture and deliver 1 to 2 mL of blood into a plain glass tube, starting the timer immediately.
- Allow the blood to clot at 37°C and record the whole-blood clotting time as a supplementary observation.
- Incubate the clotted specimen at 37°C for a fixed interval, typically one hour after clot formation, to allow the consumption reaction to reach completion.
- Centrifuge the specimen and carefully harvest the serum without disturbing the clot.
- Prewarm a reaction mixture containing tissue thromboplastin reagent, a fibrinogen source such as adsorbed bovine or human plasma, and calcium chloride at 37°C.
- Add the patient serum to the reaction mixture and record the time from addition to fibrin clot formation; this interval is the serum prothrombin time.
- Repeat the procedure with the parallel normal control specimen and compare results.
Interpretation of Results
- Normal result: a markedly prolonged serum prothrombin time indicates efficient prothrombin consumption and intact intrinsic thromboplastin generation.
- Abnormal result: a shortened serum prothrombin time indicates poor prothrombin consumption, suggesting deficiency or dysfunction of factor VIII, factor IX, factor XI, factor XII, or platelet factor 3, or the presence of a circulating anticoagulant.
- Correction studies: normalization after addition of adsorbed plasma suggests factor VIII or XI deficiency; correction by normal serum suggests factor IX deficiency; correction by phospholipid substitute suggests a platelet factor 3 defect.
Quality Control and Standardization
Reliable results depend on strict adherence to pre-analytical and analytical controls aligned with recognized guidance such as CLSI documents on coagulation specimen collection and handling and the quality management requirements of ISO 15189. Key measures include the use of clean glassware, precise temperature control at 37°C, standardized incubation times, parallel normal controls, duplicate determinations, reagent integrity checks, participation in external quality assessment, and documented validation of locally established reference intervals. The assay is moderately sensitive and may miss mild factor deficiencies, so abnormal or clinically discordant results should be confirmed with specific factor assays and APTT-based mixing studies performed by accredited third-party laboratories or specialized hemostasis laboratories.
Applications
The prothrombin consumption test is applied in several diagnostic and educational contexts:
- Screening for hemophilia A (factor VIII deficiency), hemophilia B (factor IX deficiency), and factor XI deficiency, particularly in settings where automated factor assays are not available.
- Evaluating platelet factor 3 availability and screening for platelet procoagulant dysfunction associated with qualitative platelet disorders.
- Detecting circulating anticoagulants that interfere with thromboplastin generation, when interpreted alongside mixing studies.
- Providing an integrated functional assessment of the intrinsic pathway that complements the APTT, especially when APTT results are equivocal.
- Supporting hemostasis teaching programs and research studies on coagulation cascade physiology.
- Serving as a low-cost screening tool in resource-limited or point-of-care laboratory environments.
FAQ
How does the prothrombin consumption test differ from the prothrombin time (PT)?
The prothrombin time measures the extrinsic and common pathways using citrated plasma to which tissue thromboplastin and calcium are added. The prothrombin consumption test instead measures residual prothrombin in serum after native blood has clotted, thereby reflecting the efficiency of the intrinsic pathway and platelet factor 3 during clot formation.
What does an abnormal result indicate?
A shortened serum prothrombin time indicates poor prothrombin consumption, which points to impaired thromboplastin generation. The most common causes are deficiencies of factors VIII, IX, XI, or XII, defective platelet factor 3 availability, or circulating inhibitors. Confirmatory factor assays and mixing studies are required for definitive diagnosis.
What is the normal reference range?
Reference values vary by laboratory and reagent system. In many protocols, a serum prothrombin time greater than approximately 25 seconds after standardized incubation is considered normal. Each laboratory must validate its own cutoff in accordance with ISO 15189 and relevant clinical laboratory standards.
Why has the test been largely replaced by modern methods?
Automated APTT testing, specific clotting factor assays, platelet function analyzers, and genetic testing offer greater sensitivity, quantification, and throughput. The prothrombin consumption test remains useful, however, as an inexpensive integrated screening assay and as an educational tool for understanding intrinsic pathway physiology.
What precautions are critical for accurate testing?
Clean venipuncture without tissue fluid contamination, non-siliconized glass tubes, strict 37°C temperature control, standardized incubation periods, hemolysis-free serum, parallel normal controls, and prompt testing are all essential to avoid falsely shortened or prolonged results.
Can medications affect the result?
Yes. Anticoagulant therapy, including heparin and vitamin K antagonists, and drugs that impair platelet function can alter prothrombin consumption. Clinicians should document all medications and, where appropriate, repeat testing after the interfering agent has been discontinued under medical supervision.